Skip to main content
TipRanks
Go Ultimate75% OFF

Newron Pharmaceuticals SpA (0QOI) Share Price & Analysis

1 Followers

0QOI Stock Chart & Stats

CHF 8.71-CHF 0.14(-1.58%)
At close: 4:30 PM GMT
CHF7.5CHF10CHF12.5Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
CHF 8.71 - CHF 8.84
52-Week Range
CHF 6.49 - CHF 31.85
Previous Close
CHF 8.85
Volume
N/A
Average Volume (3M)
1,161
Market Cap
CHF 181.80M
Enterprise Value
CHF 273.34M
Total Cash (Recent Filing)
CHF 32.99M
Total Debt (Recent Filing)
CHF 39.16M
Price to Earnings (P/E)
―
Beta
1.80
Next Earnings
Mar 16, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

CNS Therapeutic Focus

A focused pipeline in serious neurological and psychiatric disorders gives Newron a clear therapeutic mission and the potential to build expertise around complex CNS development. If candidates progress, this specialization can support partnering interest and multiple future development opportunities.

Partnering-Based Revenue Model

The partnering model can provide several sources of economic value from a successful candidate, including upfront consideration, development and commercial milestones, and royalties. This structure may help monetize innovation without requiring Newron to build a large commercial organization itself.

Improved Cash Generation

The sharp improvement in operating and free cash flow provides a meaningful financial positive relative to cash burn in 2021–2024. Sustained conversion would improve funding capacity for clinical work and reduce reliance on external financing, although consistency remains unproven.

Bears Say

Negative Equity And Leverage

Negative equity and substantial debt materially restrict financial flexibility. They increase refinancing and dilution risk, potentially forcing Newron to raise capital or adjust development plans on unfavorable terms, while leaving less balance-sheet capacity to absorb setbacks in clinical or partnering activity.

Sharp Revenue And Earnings Deterioration

The steep revenue decline and return to sizable losses show that recent financial performance is not stable. Weak operating margins can limit internally funded research and increase dependence on milestone receipts, licensing transactions, or external capital to sustain development.

Recurring Losses And Episodic Revenue

Recurring losses across most years indicate that profitability has not yet become a durable feature of the business. Dependence on episodic revenue events makes results difficult to forecast and may produce uneven funding for the clinical pipeline, especially when transactions or milestones are delayed.

Newron Pharmaceuticals SpA News

0QOI FAQ

What was Newron Pharmaceuticals SpA’s price range in the past 12 months?
Newron Pharmaceuticals SpA lowest share price was CHF6.49 and its highest was CHF31.85 in the past 12 months.
What is Newron Pharmaceuticals SpA’s market cap?
Newron Pharmaceuticals SpA’s market cap is CHF181.80M.
When is Newron Pharmaceuticals SpA’s upcoming earnings report date?
Newron Pharmaceuticals SpA’s next earnings report is estimated for Mar 16, 2027 (not yet confirmed), which is in 119 days.
How were Newron Pharmaceuticals SpA’s earnings last quarter?
Newron Pharmaceuticals SpA released its earnings results on Sep 22, 2026. The company reported -CHF0.742 earnings per share for the quarter, missing the consensus estimate of -CHF0.176 by -CHF0.566.
Is Newron Pharmaceuticals SpA overvalued?
According to Wall Street analysts Newron Pharmaceuticals SpA’s price is currently Undervalued.
Does Newron Pharmaceuticals SpA pay dividends?
Newron Pharmaceuticals SpA does not currently pay dividends.
What is Newron Pharmaceuticals SpA’s EPS estimate?
Newron Pharmaceuticals SpA’s EPS estimate is -0.71.
How many shares outstanding does Newron Pharmaceuticals SpA have?
Newron Pharmaceuticals SpA has 21,238,867 shares outstanding.
What happened to Newron Pharmaceuticals SpA’s price movement after its last earnings report?
Newron Pharmaceuticals SpA reported an EPS of -CHF0.742 in its last earnings report, missing expectations of -CHF0.176. Following the earnings report the stock price went down -3.678%.
Which hedge fund is a major shareholder of Newron Pharmaceuticals SpA?
Currently, no hedge funds are holding shares in GB:0QOI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology